Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report

A week of positive clinical outcomes that drove up share prices was bogged down by a trio of product discontinuations in once highly promising therapeutic classes.

The past seven days saw Merck & Co. Inc. (NYSE:MRK) discontinue development of two next-generation checkpoint inhibitors that were once poised as Keytruda pembrolizumab follow-ons...